PATENT CLAIM ANALYSIS

Application Number: 16164282
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "279000"]

Abstract:
Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.

Claim (Index 17):
The package according to  claim 16 , wherein said patient is a neonate suffering from neonatal opioid withdrawal syndrome.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.13158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14416421', '14923630', '10566121', '14490470', '14469063']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7009499972371999
- 35 USC 102 Novelty (BERT): 0.4941701098198013
- Combined Prediction Score: 0.68027200849546
- Mean Citation Score: 197.053192
- Max Citation Score: 201.835
- Similarity Product: 148.6103749576211

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test